|
HRP20221048T1
(hr)
|
2010-08-31 |
2022-11-11 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za isporuku rna koja kodira imunogen
|
|
SMT202200311T1
(it)
|
2010-08-31 |
2022-09-14 |
Glaxosmithkline Biologicals Sa |
Liposomi pegilati per somministrare rna codificante un immunogene
|
|
EP3998064A1
(en)
|
2011-06-08 |
2022-05-18 |
Translate Bio, Inc. |
Cleavable lipids
|
|
PT2717893T
(pt)
|
2011-06-08 |
2019-08-20 |
Translate Bio Inc |
Composições de nanopartículas lipídicas e métodos para transferência de arnm
|
|
IL289934B2
(en)
|
2014-06-25 |
2023-04-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
CN114085198A
(zh)
|
2015-06-29 |
2022-02-25 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
RS63986B1
(sr)
*
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP4714454A2
(en)
|
2016-10-26 |
2026-03-25 |
Acuitas Therapeutics Inc. |
Lipid nanoparticle formulations
|
|
IL317855A
(en)
*
|
2016-10-26 |
2025-02-01 |
Acuitas Therapeutics Inc |
mRNA vaccines with lipid nanoparticles
|
|
US20190274968A1
(en)
*
|
2016-10-27 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11241490B2
(en)
|
2017-01-11 |
2022-02-08 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified RNA for inducing an immune response against zika virus
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
|
WO2019012336A2
(en)
|
2017-03-17 |
2019-01-17 |
Newcastle University |
ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
EP3618859A4
(en)
|
2017-04-27 |
2021-05-05 |
Vanderbilt University |
HEPATITIS C VIRUS SEQUENCES AND METHODS OF USING THEREFORE
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US11786607B2
(en)
*
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
JP7461872B2
(ja)
*
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
SG11202008225PA
(en)
|
2018-04-17 |
2020-11-27 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
EP3793689A1
(en)
|
2018-05-15 |
2021-03-24 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CA3100254A1
(en)
*
|
2018-05-24 |
2019-11-28 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
US20200016274A1
(en)
|
2018-05-30 |
2020-01-16 |
Translate Bio, Inc. |
Messenger rna vaccines and uses thereof
|
|
JP7441802B2
(ja)
|
2018-05-30 |
2024-03-01 |
トランスレイト バイオ， インコーポレイテッド |
ビタミンカチオン性脂質
|
|
CA3100214A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
WO2019232097A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
EP4591888A3
(en)
|
2018-06-18 |
2026-01-21 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CN109142288B
(zh)
*
|
2018-07-13 |
2020-10-02 |
河南师范大学 |
利用荧光光谱法测定囊泡生成的方法
|
|
WO2020023533A1
(en)
|
2018-07-23 |
2020-01-30 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
|
AU2019333042B2
(en)
|
2018-08-29 |
2025-06-19 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
EP3853202A1
(en)
*
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP4613367A1
(en)
|
2018-09-21 |
2025-09-10 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
AU2019361129A1
(en)
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN112888451A
(zh)
|
2018-10-19 |
2021-06-01 |
川斯勒佰尔公司 |
信使rna的无泵包封
|
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
AU2019377525B2
(en)
|
2018-11-09 |
2025-10-16 |
Translate Bio, Inc. |
Multi-PEG lipid compounds
|
|
JP7483294B2
(ja)
|
2018-11-09 |
2024-05-15 |
トランスレイト バイオ， インコーポレイテッド |
層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
|
|
US12280147B2
(en)
|
2018-11-09 |
2025-04-22 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
CA3119449A1
(en)
|
2018-11-12 |
2020-05-22 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
|
US12257305B2
(en)
|
2018-11-21 |
2025-03-25 |
Translate Bio, Inc. |
Cationic lipid compounds
|
|
CA3118034A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
JP2022516356A
(ja)
|
2019-01-07 |
2022-02-25 |
トランスレイト バイオ， インコーポレイテッド |
原発性線毛機能不全症の治療のための組成物および方法
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
WO2020214946A1
(en)
|
2019-04-18 |
2020-10-22 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
US20220233444A1
(en)
|
2019-04-22 |
2022-07-28 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
AU2020261419B2
(en)
*
|
2019-04-25 |
2026-01-29 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
EP3962902A1
(en)
*
|
2019-05-03 |
2022-03-09 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
CN114375334B
(zh)
|
2019-06-07 |
2026-03-20 |
斯克里贝治疗公司 |
工程化CasX系统
|
|
EP3986915A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
US20220305117A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
EP3986563A1
(en)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
CN114401942B
(zh)
|
2019-06-21 |
2024-01-26 |
川斯勒佰尔公司 |
三(羟甲基)甲基甘氨酸和柠檬酸脂质
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
JP7586886B2
(ja)
|
2019-07-08 |
2024-11-19 |
トランスレイト バイオ， インコーポレイテッド |
改善されたｍＲＮＡ装填脂質ナノ粒子、およびそれを作製するプロセス
|
|
CN114423869A
(zh)
|
2019-07-19 |
2022-04-29 |
旗舰先锋创新Vi有限责任公司 |
重组酶组合物和使用方法
|
|
US12144871B2
(en)
|
2019-07-23 |
2024-11-19 |
Translate Bio, Inc. |
Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
|
|
GEP20257820B
(en)
|
2019-08-14 |
2025-11-10 |
Acuitas Therapeutics Inc |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
JP7700101B2
(ja)
|
2019-09-06 |
2025-06-30 |
ジェネレーション バイオ カンパニー |
閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
US20240197825A1
(en)
|
2019-09-20 |
2024-06-20 |
Translate Bio, Inc. |
mRNA Encoding Engineered CFTR
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
|
WO2021081058A1
(en)
|
2019-10-21 |
2021-04-29 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
CA3154774A1
(en)
|
2019-11-22 |
2021-05-27 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
CN114845987B
(zh)
*
|
2019-12-19 |
2024-06-11 |
索尔维公司 |
用于合成双尾三胺的方法
|
|
WO2021127641A1
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
IL294073A
(en)
|
2019-12-20 |
2022-08-01 |
Translate Bio Inc |
Rectal administration of messenger rna
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
JP7793525B2
(ja)
|
2020-02-04 |
2026-01-05 |
キュアバック エスイー |
コロナウイルスワクチン
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11969480B2
(en)
|
2020-02-25 |
2024-04-30 |
Translate Bio, Inc. |
Processes of preparing mRNA-loaded lipid nanoparticles
|
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
KR20220154772A
(ko)
*
|
2020-03-13 |
2022-11-22 |
주식회사 바이오오케스트라 |
Pgc-1a 발현을 사용하는 진단 방법
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
US12534435B2
(en)
|
2020-03-27 |
2026-01-27 |
Generation Bio Co. |
Lipids and nanoparticle compositions thereof
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2021205077A1
(en)
|
2020-04-09 |
2021-10-14 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
KR102924173B1
(ko)
|
2020-04-09 |
2026-02-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 나노입자 조성물
|
|
MX2022012683A
(es)
|
2020-04-09 |
2023-01-11 |
Verve Therapeutics Inc |
Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
CN113874507A
(zh)
|
2020-04-09 |
2021-12-31 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
US12023376B1
(en)
|
2020-04-17 |
2024-07-02 |
Triad National Security, Llc |
Conserved region T cell vaccines for coronavirus and methods of use
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
WO2021226436A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
EP4146680A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
US12514932B2
(en)
|
2020-05-14 |
2026-01-06 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
|
WO2021231901A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
JP2023526422A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
コロナウイルス抗原組成物及びそれらの使用
|
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
|
CN116018405A
(zh)
|
2020-05-29 |
2023-04-25 |
旗舰先锋创新Vi有限责任公司 |
Trem组合物及其相关方法
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
JP2023530974A
(ja)
|
2020-06-15 |
2023-07-20 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーのためのアデノ随伴ウイルスベクター送達
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
DK4182297T3
(da)
|
2020-07-16 |
2025-12-01 |
Acuitas Therapeutics Inc |
Kationiske lipider til brug i lipid-nanopartikler
|
|
EP4189098A1
(en)
|
2020-07-27 |
2023-06-07 |
Anjarium Biosciences AG |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
MX2023002439A
(es)
|
2020-09-03 |
2023-05-09 |
Flagship Pioneering Innovations Vi Llc |
Composiciones immunogénicas y usos de las mismas.
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
JP2023544197A
(ja)
|
2020-10-06 |
2023-10-20 |
トランスレイト バイオ， インコーポレイテッド |
脂質ナノ粒子の改善された方法および製剤
|
|
WO2022081544A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
EP4229208A4
(en)
|
2020-10-14 |
2024-10-30 |
George Mason Research Foundation, Inc. |
METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF
|
|
AU2021373892A1
(en)
|
2020-11-09 |
2023-07-06 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
|
US11591544B2
(en)
|
2020-11-25 |
2023-02-28 |
Akagera Medicines, Inc. |
Ionizable cationic lipids
|
|
AU2021386737A1
(en)
|
2020-11-25 |
2023-07-13 |
Translate Bio, Inc. |
Stable liquid lipid nanoparticle formulations
|
|
EP4256054A1
(en)
|
2020-12-03 |
2023-10-11 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
KR20230135585A
(ko)
|
2020-12-23 |
2023-09-25 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변형된 trem의 조성물 및 이의 용도
|
|
JP2024501022A
(ja)
|
2020-12-28 |
2024-01-10 |
アークトゥルス セラピューティクス， インコーポレイテッド |
Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ）
|
|
CN116981692A
(zh)
|
2021-01-14 |
2023-10-31 |
翻译生物公司 |
递送mRNA编码的抗体的方法和组合物
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
IL305021A
(en)
|
2021-02-08 |
2023-10-01 |
Univ Texas |
Unsaturated Dendrimer Compositions, Related Formulations, and Methods of Using Them
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022192086A1
(en)
*
|
2021-03-06 |
2022-09-15 |
Gumrukcu Serhat |
Compositions and methods for treating and preventing coronavirus infections
|
|
WO2022204219A1
(en)
|
2021-03-22 |
2022-09-29 |
Recode Therapeutics, Inc. |
Compositions and methods for targeted delivery to cells
|
|
JP2024511437A
(ja)
|
2021-03-23 |
2024-03-13 |
リコード セラピューティクス，インク． |
ポリヌクレオチド組成物、関連製剤、およびその使用方法
|
|
US20250268994A1
(en)
|
2021-03-25 |
2025-08-28 |
Translate Bio, Inc. |
Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
JP2024515668A
(ja)
|
2021-04-19 |
2024-04-10 |
トランスレイト バイオ， インコーポレイテッド |
Ｍｒｎａの送達のための改善された組成物
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
EP4310071A4
(en)
|
2021-05-28 |
2024-11-20 |
Beijing Tricisionbio Therapeutics Inc. |
LIPID COMPOUND AND USE THEREOF IN THE ADMINISTRATION OF NUCLEIC ACID
|
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
|
EP4362920A1
(en)
|
2021-07-01 |
2024-05-08 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
EP4387659A4
(en)
|
2021-08-18 |
2025-09-03 |
Univ Pennsylvania |
MRNA VACCINES DIRECTED AGAINST TICK SALIVARY PROTEINS AND METHODS OF USE THEREOF
|
|
CN115710192B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN118043466A
(zh)
|
2021-09-03 |
2024-05-14 |
葛兰素史克生物有限公司 |
自扩增信使核糖核酸中核苷酸碱基的取代
|
|
EP4395748A1
(en)
|
2021-09-03 |
2024-07-10 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
JP2024534523A
(ja)
|
2021-09-21 |
2024-09-20 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたｃａｓｘリプレッサー系
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
AU2022370530A1
(en)
|
2021-10-18 |
2024-05-02 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
JP2024539512A
(ja)
|
2021-10-22 |
2024-10-28 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａワクチン組成物
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
CA3238292A1
(en)
|
2021-11-16 |
2023-05-25 |
Alessandra Bartolozzi |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4436549A1
(en)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CN118488834A
(zh)
|
2021-11-23 |
2024-08-13 |
赛欧生物医药股份有限公司 |
细菌源性脂质组合物和其用途
|
|
JP2024541467A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
コロナウイルス免疫原組成物及びそれらの使用
|
|
JP2024541466A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
水痘帯状疱疹ウイルス免疫原組成物及びその使用
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
CA3242406A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Fluorinated cationic lipids for use in lipid nanoparticles
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240122872A
(ko)
|
2021-12-16 |
2024-08-13 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자에 사용하기 위한 플루오르화 양이온성 지질
|
|
AU2022413687A1
(en)
|
2021-12-17 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
EP4452239A1
(en)
|
2021-12-20 |
2024-10-30 |
Sail Biomedicines, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
JP2025500358A
(ja)
|
2021-12-23 |
2025-01-09 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
抗膜融合ポリペプチドをコードする環状ポリリボヌクレオチド
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
US20250345416A1
(en)
|
2022-01-27 |
2025-11-13 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
TW202345863A
(zh)
*
|
2022-02-09 |
2023-12-01 |
美商現代公司 |
黏膜投與方法及調配物
|
|
US20250250227A1
(en)
|
2022-02-28 |
2025-08-07 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Amino lipid compound, preparation method therefor, composition thereof and use thereof
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
CN116813493A
(zh)
*
|
2022-03-21 |
2023-09-29 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
US20250205167A1
(en)
|
2022-03-25 |
2025-06-26 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2023191628A1
(en)
|
2022-03-30 |
2023-10-05 |
Bioneedle Drug Delivery B.V. |
A process for storing biologically active constructs in a biodegradable material
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
ワクチン及び関連する方法
|
|
CN116969851A
(zh)
*
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CN119487196A
(zh)
|
2022-05-13 |
2025-02-18 |
旗舰创业创新七公司 |
双链dna组合物及相关方法
|
|
JP2025516674A
(ja)
|
2022-05-13 |
2025-05-30 |
ビオンテック エスエー |
Ｈｉｖを標的とするｒｎａ組成物
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
IL316504A
(en)
|
2022-05-25 |
2024-12-01 |
BioNTech SE |
RNA compositions for the delivery of monkeypox antigens and related methods
|
|
KR20250031230A
(ko)
|
2022-05-25 |
2025-03-06 |
아카제라 메디신즈, 인크. |
핵산 전달을 위한 지질 나노입자 및 이의 사용 방법
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
US20250333767A1
(en)
|
2022-06-02 |
2025-10-30 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
AU2023283348A1
(en)
|
2022-06-07 |
2025-01-09 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
EP4314267A1
(en)
|
2022-06-07 |
2024-02-07 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
JP2025521912A
(ja)
|
2022-07-06 |
2025-07-10 |
モレキュラー アクシオム エルエルシー |
膵臓癌を治療するための組成物及び方法
|
|
US20250360199A1
(en)
|
2022-07-07 |
2025-11-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Immunogens and methods for inducing an immune response
|
|
US20260015315A1
(en)
*
|
2022-07-15 |
2026-01-15 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Amino lipid compound, preparation method therefor, composition thereof and application thereof
|
|
AU2023316579A1
(en)
|
2022-07-29 |
2025-02-13 |
Fujifilm Corporation |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
|
|
CA3261283A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory Proteins and Associated Methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
CN119654141A
(zh)
|
2022-08-18 |
2025-03-18 |
苏州艾博生物科技有限公司 |
脂质纳米颗粒的组合物
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
US20260069712A1
(en)
|
2022-08-23 |
2026-03-12 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
AU2023334610A1
(en)
|
2022-08-31 |
2025-03-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
AU2023347390A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023347387A1
(en)
|
2022-09-23 |
2025-04-10 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
IL319682A
(en)
|
2022-10-06 |
2025-05-01 |
BioNTech SE |
RNA complexes targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
CN120682120A
(zh)
*
|
2022-11-03 |
2025-09-23 |
上海环码生物医药有限公司 |
脂质化合物、脂质纳米颗粒和药物组合物
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
JP2025537178A
(ja)
|
2022-11-08 |
2025-11-14 |
オーナ セラピューティクス， インコーポレイテッド |
環状ｒｎａ組成物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
WO2024112652A1
(en)
|
2022-11-21 |
2024-05-30 |
Translate Bio, Inc. |
Compositions of dry powder formulations of messenger rna and methods of use thereof
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
IL320873A
(en)
|
2022-12-01 |
2025-07-01 |
Generation Bio Co |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them
|
|
CN120615013A
(zh)
|
2022-12-01 |
2025-09-09 |
世代生物公司 |
用于细胞靶向的隐形脂质纳米颗粒组合物
|
|
EP4626444A2
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4626859A1
(en)
*
|
2022-12-02 |
2025-10-08 |
Prime Medicine, Inc. |
Lipid nanoparticle (lnp) delivery systems and formulations
|
|
CN120693181A
(zh)
|
2022-12-08 |
2025-09-23 |
瑞科德治疗公司 |
脂质纳米颗粒组合物及其用途
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
CN120456919A
(zh)
|
2022-12-19 |
2025-08-08 |
葛兰素史克生物有限公司 |
乙型肝炎组合物
|
|
AR131438A1
(es)
|
2022-12-20 |
2025-03-19 |
Sanofi Sa |
VACUNA DE ARNm DE RINOVIRUS
|
|
WO2024133635A1
(en)
|
2022-12-23 |
2024-06-27 |
Biontech Delivery Technologies Gmbh |
Composition
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
CN118324841A
(zh)
|
2023-01-10 |
2024-07-12 |
辽宁键凯科技有限公司 |
一种类固醇-阳离子脂质化合物及其应用
|
|
CN118359516A
(zh)
*
|
2023-01-18 |
2024-07-19 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
|
WO2024163905A1
(en)
|
2023-02-03 |
2024-08-08 |
Genzyme Corporation |
Hsc-specific antibody conjugated lipid nanoparticles and uses thereof
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
WO2024173836A2
(en)
|
2023-02-17 |
2024-08-22 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
IL322201A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA structures containing modified uracil
|
|
WO2024181917A1
(en)
*
|
2023-02-28 |
2024-09-06 |
Agency For Science, Technology And Research |
A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof
|
|
AU2024233180A1
(en)
|
2023-03-08 |
2025-09-25 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
CN121358494A
(zh)
|
2023-03-15 |
2026-01-16 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
CN118666726A
(zh)
*
|
2023-03-17 |
2024-09-20 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
AU2024242151A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
AU2024248139A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024216128A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
EP4698156A1
(en)
|
2023-04-17 |
2026-02-25 |
Sanofi Pasteur Inc. |
Reconstitutable dry powder formulations and methods of use thereof
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
CN121399470A
(zh)
|
2023-05-03 |
2026-01-23 |
马尼福尔德生物技术有限公司 |
用于高通量蛋白质递送、筛选和检测的方法和组合物
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
CN121666232A
(zh)
|
2023-05-31 |
2026-03-13 |
开普斯坦治疗公司 |
脂质纳米颗粒制剂和组合物
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025006385A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel malaria vaccine comprising ama1 and ron2 antigens
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
AU2024299365A1
(en)
|
2023-07-24 |
2026-01-08 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
AU2024299627A1
(en)
|
2023-07-25 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
AU2024316307A1
(en)
|
2023-08-03 |
2026-02-26 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025036992A1
(en)
|
2023-08-16 |
2025-02-20 |
CureVac SE |
Rna conjugates
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025043730A1
(en)
*
|
2023-09-01 |
2025-03-06 |
Yoltech Therapeutics Co., Ltd |
Lipid compounds for delivery of therapeutic agents and preparation method and use thereof
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202539697A
(zh)
|
2023-11-15 |
2025-10-16 |
德商拜恩技術股份公司 |
冠狀病毒疫苗
|
|
WO2025106738A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
WO2025106806A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
US12553042B2
(en)
|
2023-12-01 |
2026-02-17 |
Recode Therapeutics, Inc. |
Method for quantifying an amount of capped messenger RNA
|
|
US12364773B2
(en)
*
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025128696A1
(en)
|
2023-12-12 |
2025-06-19 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
TW202525287A
(zh)
|
2023-12-21 |
2025-07-01 |
德商拜恩技術運輸科技有限責任公司 |
可離子化脂質
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025147604A1
(en)
|
2024-01-05 |
2025-07-10 |
Arbor Biotechnologies, Inc. |
Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
TW202543581A
(zh)
|
2024-02-12 |
2025-11-16 |
美商艾伊拉醫療公司 |
遞送組成物
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025231114A1
(en)
|
2024-05-01 |
2025-11-06 |
Acuitas Therapeutics, Inc. |
Method of using lipid nanoparticles for intramuscular delivery
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018181A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026033123A1
(en)
|
2024-08-08 |
2026-02-12 |
Sanofi Pasteur Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
WO2026033498A1
(en)
|
2024-08-09 |
2026-02-12 |
Genvax Technologies, Inc. |
Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|